Evaluation of Cardiorenal Metabolic Syndrome in Patients with Heart Failure with Preserved Ejection Fraction. How Aware Are We?
Sakarya Medical Journal, cilt.15, sa.3, ss.192-199, 2025 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 15 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.31832/smj.1684457
- Dergi Adı: Sakarya Medical Journal
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.192-199
- Anahtar Kelimeler: CRMD, Diabetes mellitus, HFpEF, Hypertension, MASLD
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Aim: Despite the prevalence of cardiorenal metabolic diseases (CRMD) in heart failure with preserved ejection fraction (HFpEF) patients and their significant complications, they are thought to be under-recognized and under-screened. In our study, we aimed to evaluate patients with HFpEF who were followed up in our internal medicine clinic. Methods: Our retrospective and cross-sectional study included 348 patients with HFpEF. Patients were evaluated according to laboratory, demographic, clinical, electrocardiographic and ultrasonographic findings. Results: Of the patients, 37.95% had diabetes mellitus, 23.3% had chronic kidney disease, 70.1% had hypertension and 59.2% had metabolic dysfunction-associated steatotic liver disease. The mean NT-proBNP level was 360.7 ± 13.7. Conclusion: We recommend that HFpEF, which is associated with increased cardiovascular mortality and morbidity in patients with CRMD, should be screened clinically and with NT-proBNP and evaluated with transthoracic echocardiography if necessary.